Clinical BioManufacturing Facility
University of Oxford
The CBF is the University of Oxford’s GMP (Good Manufacturing Practice) manufacturing facility and aims to provide the link between academic research and clinical drug development, to allow its collaborators to make rapid progress into clinical trials. It holds a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA (IMPs)) from the MHRA and is equipped to meet the demands of phase I/II clinical trials of novel biotech products.
A unique feature of OxCD3 is the fact that the entire team is based within a single square mile on the University’s Medical Sciences campus. To maximise impact, a key aim of OxCD3 is the scale-up of laboratory-based methods for device-based drug delivery and the completion of toxicology studies in preparation for clinical trials beyond the 5 year funding period. To this end, the CBF will provide invaluable assistance in enabling the iterative manufacture of up to three candidate agents to GMP in readiness for clinical trials.
Dr Sarah Moyle is Head of the Clinical BioManufacturing Facility and is responsible for the management of novel academic projects from process development, through scale-up to GMP manufacture. Dr Moyle has a background in translational research in both biotech and academic settings.